Egetis Therapeutics AB (publ) (STO:EGTX)
Sweden · Delayed Price · Currency is SEK 7.77
-0.12 (-1.52%)
Sep 2, 2026, 5:29 PM CET
Egetis Therapeutics AB Stock Forecast
Stock Price Forecast
According to 4 analysts polled by S&P Global, Egetis Therapeutics AB stock has a consensus rating of "Buy" and an average price target of kr 15.33. The average 1-year stock price forecast is 97.30% higher than the current stock price, while the lowest is kr 11.00 (+41.57%) and the highest is kr 23.00 (+196.01%).
Price Target: kr 15.33 (+97.30%)
Analyst Consensus: Buy
Price Target
Chart* Price targets were last updated on Jun 25, 2026.
Analyst Ratings
The average analyst rating for Egetis Therapeutics AB stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 3 | 3 | 3 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates kr 23.00 | Buy | Initiates | kr 23.00 | +196.01% | Jun 25, 2026 |
Financial Forecast
Revenue This Year
551.05M
from 62.40M
Increased by 783.09%
Revenue Next Year
327.79M
from 551.05M
Decreased by -40.52%
EPS This Year
-0.87
from -0.90
EPS Next Year
-0.46
from -0.87
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is SEK.